Can analysts adopt a bullish outlook for Zogenix, Inc. (NASDAQ:ZGNX)?

October 13, 2017 - By Marie Mckinney

 Can analysts adopt a bullish outlook for Zogenix, Inc. (NASDAQ:ZGNX)?

Zogenix, Inc. (NASDAQ:ZGNX) Ratings Coverage

Among 6 analysts covering Zogenix (NASDAQ:ZGNX), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Zogenix had 14 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Stifel Nicolaus with “Buy” on Thursday, September 21. The company was upgraded on Friday, September 29 by William Blair. The rating was upgraded by Zacks on Saturday, August 15 to “Hold”. Brean Capital maintained Zogenix, Inc. (NASDAQ:ZGNX) on Thursday, September 17 with “Buy” rating. Stifel Nicolaus maintained it with “Buy” rating and $55.0 target in Friday, September 29 report. Leerink Swann maintained it with “Outperform” rating and $27 target in Tuesday, August 11 report. The stock of Zogenix, Inc. (NASDAQ:ZGNX) earned “Buy” rating by Stifel Nicolaus on Monday, June 26. Zacks upgraded Zogenix, Inc. (NASDAQ:ZGNX) on Thursday, August 6 to “Sell” rating. The rating was maintained by Brean Capital on Friday, August 14 with “Buy”. The stock of Zogenix, Inc. (NASDAQ:ZGNX) earned “Outperform” rating by Leerink Swann on Monday, October 2. Below is a list of Zogenix, Inc. (NASDAQ:ZGNX) latest ratings and price target changes.

02/10/2017 Broker: Leerink Swann Old Rating: Outperform New Rating: Outperform Old Target: $20 New Target: $50 Maintain
29/09/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $55.0 Maintain
29/09/2017 Broker: William Blair Rating: Buy Upgrade
21/09/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $26.0 Maintain
06/09/2017 Broker: Mizuho Rating: Buy New Target: $28.0
26/06/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $26.0000 Maintain

The stock decreased 0.99% or $0.4 during the last trading session, reaching $39.85. About shares traded. Zogenix, Inc. (NASDAQ:ZGNX) has risen 52.57% since October 13, 2016 and is uptrending. It has outperformed by 35.87% the S&P500.

Zogenix, Inc. is a pharmaceutical company engaged in developing and commercializing central nervous system therapies that address specific clinical needs for people living with orphan and other CNS disorders. The company has market cap of $1.26 billion. The Company’s primary area of therapeutic focus is epilepsy and related seizure disorders. It currently has negative earnings. The Company’s lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.

More notable recent Zogenix, Inc. (NASDAQ:ZGNX) news were published by: Seekingalpha.com which released: “Zogenix: Investors Bet Heavy On ZX008 For Dravet Syndrome” on October 02, 2017, also Globenewswire.com with their article: “Zogenix Announces Closing of Public Offering of Common Stock, Including Full …” published on October 05, 2017, Seekingalpha.com published: “Zogenix’ ZX008 Is The Real Deal” on September 30, 2017. More interesting news about Zogenix, Inc. (NASDAQ:ZGNX) were released by: Fool.com and their article: “Why Zogenix Inc. Stock More Than Doubled Today” published on September 29, 2017 as well as Seekingalpha.com‘s news article titled: “Daily Insider Ratings Round Up 10/3/17: ZGNX, SOR” with publication date: October 03, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Twitter Auto Publish Powered By : XYZScripts.com